From research to patient access
Psychedelic therapies are moving from clinical trials toward healthcare systems — but the path is complex. We break down the science, regulations, economics, and barriers shaping how these treatments reach the people who need them, with a focus on Europe and the United States.
The Big Picture
Landscape overview of psychedelic therapy implementation, key takeaways, and future outlook across Europe and the US.
Critical Observations from Collaborators
The integration of psychedelic therapies into European healthcare systems represents a complex challenge that extends beyond the scope of traditional...
Introduction to Psychedelics and Reimbursement
Psychedelic substances have been used for millennia in various indigenous cultures for religious, spiritual, and healing purposes. For instance,...
Reimbursement Pathways for Psychedelic Therapies: An Overview
Mental health disorders impose a severe and growing societal and economic burden across Europe. Both national governments and the European Union (EU) now...
The Science
Drug development stages, clinical trial phases, and the evidence base underpinning psychedelic therapies.
Regulatory Pathways
Approval processes, regulatory frameworks, and how different regions are approaching psychedelic therapy authorization.
Who Pays
Health economics, health technology assessment, reimbursement models, and insurance coverage for psychedelic therapies.
Payer and Health Technology Assessments
Securing access to psychedelic therapies requires working with payers and health technology assessment (HTA) bodies after regulatory approval. These...
Reimbursement Landscape in Europe
In Europe, while the European Medicines Agency (EMA) handles drug approvals centrally for most countries, each country makes its own decisions about...
Barriers & Challenges
Stigma, supply chain constraints, training requirements, and political hurdles standing in the way of implementation.
Solutions & Models
Innovative approaches, therapy delivery models, and policy recommendations for advancing psychedelic therapy access.
Potential Reimbursement and Access Pathways
As psychedelic therapies move closer to approval in Europe, healthcare systems face a crucial question: How will patients access these treatments? The path...
Solutions and Recommendations
This chapter explores practical solutions for integrating psychedelic therapies into European healthcare systems. Building on the previous chapter's...
Access & Equity
Global access considerations, underserved populations, equitable distribution, and emerging pathways to broad availability.